Lionco Pharmaceutical Group Co., Ltd. (603669) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lionco Pharmaceutical Group Co., Ltd.

Why is Lionco Pharmaceutical Group Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 3.26%

The company has been able to generate a Return on Capital Employed (avg) of 3.26% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -20.24% and Operating profit at -196.08% over the last 5 years

Flat results in Mar 25

NET PROFIT(HY) At CNY -106.51 MM has Grown at -61.39%
INTEREST(HY) At CNY 25.94 MM has Grown at 2,694.37%
NET SALES(Q) At CNY 49.45 MM has Fallen at -35.11%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -31.09%, its profits have fallen by -21.3%

Below par performance in long term as well as near term

Along with generating -31.09% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lionco Pharmaceutical Group Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Lionco Pharmaceutical Group Co., Ltd.

-31.09%

0.12

52.18%

China Shanghai Composite

14.77%

1.01

14.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-20.24%

EBIT Growth (5y)

-196.08%

EBIT to Interest (avg)

-21.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

0.21

Tax Ratio

2.65%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

3.26%

ROE (avg)

2.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.49

EV to EBIT

-33.40

EV to EBITDA

-48.02

EV to Capital Employed

5.38

EV to Sales

10.00

PEG Ratio

Dividend Yield

ROCE (Latest)

-16.10%

ROE (Latest)

-18.37%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET SALES(HY)

At CNY 195.58 MM has Grown at 62.4%

INVENTORY TURNOVER RATIO(HY)

Highest at 5.65%

-30What is not working for the Company

NET PROFIT(HY)

At CNY -106.51 MM has Grown at -61.39%

INTEREST(HY)

At CNY 25.94 MM has Grown at 2,694.37%

NET SALES(Q)

At CNY 49.45 MM has Fallen at -35.11%

PRE-TAX PROFIT(Q)

At CNY -15.24 MM has Fallen at -54.52%

OPERATING CASH FLOW(Y)

Lowest at CNY -85.97 MM

DEBT-EQUITY RATIO (HY)

Highest at 1.7 %

RAW MATERIAL COST(Y)

Grown by 40.78% (YoY

CASH AND EQV(HY)

Lowest at CNY 555.94 MM

Here's what is working for Lionco Pharmaceutical Group Co., Ltd.

Inventory Turnover Ratio

Highest at 5.65%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Lionco Pharmaceutical Group Co., Ltd.

Interest

At CNY 25.94 MM has Grown at 2,694.37%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 49.45 MM has Fallen at -35.11%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit

At CNY -15.24 MM has Fallen at -54.52%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -18.48 MM has Fallen at -39.97%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Debt-Equity Ratio

Highest at 1.7 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Cash Flow

Lowest at CNY -85.97 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Lowest at CNY 49.45 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Cash and Eqv

Lowest at CNY 555.94 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 40.78% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales